Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.31 |
| ▸ | ATXN2 | Q99700 | 2/20 | 0.31 |
| ▸ | ME2 | P23368 | 1/20 | 0.31 |
| ▸ | ME1 | P48163 | 1/20 | 0.31 |
| ▸ | ME3 | Q16798 | 1/20 | 0.31 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.30 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.30 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14553786 | 0.93 | KMT2A (0.33) | KMT2AMEN1ALDH1A1TSHRENPP2 | |
| SCHEMBL1684536 | 0.93 | KMT2A (0.34) | KMT2AMEN1ALDH1A1TSHRENPP2 | |
| SCHEMBL12239781 | 0.82 | ALDH1A1 (0.45) | KMT2AMEN1ALDH1A1TSHRME2 | |
| SCHEMBL12239194 | 0.82 | MEN1 (0.33) | KMT2AMEN1ALDH1A1ENPP2ATXN2 | |
| SCHEMBL12238850 | 0.82 | EPHX2 (0.36) | KMT2AMEN1ALDH1A1TSHRENPP2 | |
| SCHEMBL12238986 | 0.82 | YAP1 (0.40) | ALDH1A1 | |
| SCHEMBL12824794 | 0.81 | ME2 (0.38) | KMT2AMEN1ALDH1A1TSHRENPP2 | |
| SCHEMBL12301813 | 0.81 | ME2 (0.34) | KMT2AMEN1ALDH1A1ENPP2ATXN2 | |
| SCHEMBL2844338 | 0.80 | KMT2A (0.42) | KMT2AMEN1ALDH1A1TSHRENPP2 | |
| SCHEMBL12238983 | 0.76 | PLAU (0.40) | KMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8039472-B2 | Pyrazine-2-carboxamide derivatives to treat diseases mediated by blockade of the epithelial sodium channel | NOVARTIS AG (CH) | 2011-10-18 | — | — | US | disclosed |
| US-20100130506-A1 | Organic Compounds | NOVARTIS AG | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130506-A1 | Organic Compounds | OR10J3, REN, CACNA1E | KMT2A 4325/4885MEN1 854/4885ALDH1A1 1317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.